ALXN Share Price

Open 135.18 Change Price %
High 135.18 1 Day -2.38 -1.77
Low 131.19 1 Week -4.96 -3.62
Close 131.97 1 Month 12.98 10.91
Volume 1828906 1 Year -23.55 -15.14
52 Week High 162.00
52 Week Low 109.12
ALXN Important Levels
Resistance 2 135.67
Resistance 1 134.14
Pivot 132.78
Support 1 129.80
Support 2 128.27
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

ALXN Technical Analysis 1.5
As on 20th Jan 2017 ALXN Share Price closed @ 131.97 and we RECOMMEND Sell for LONG-TERM with Stoploss of 132.31 & Buy for SHORT-TERM with Stoploss of 125.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALXN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ALXN Other Details
Segment EQ
Market Capital 17547872256.00
Sector Healthcare
Industry Biotechnology
Offical website
ALXN Address
352 Knotter Drive
Cheshire, CT 06410
United States
Phone: 203-272-2596
Fax: 203-271-8198
Interactive Technical Analysis Chart Alexion Pharmaceuticals, Inc. ( ALXN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Alexion Pharmaceuticals, Inc.
ALXN Business Profile
Alexion Pharmaceuticals, Inc. (Alexion), incorporated on January 28, 1992, is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. The Company is also evaluating other indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and it is progressing with other biotechnology product candidates in ultra-rare and severe disorders, which are in various stages of development. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, including transplant rejection and neurology. Soliris is a humanized antibody which, administered at the doses prescribed, generally blocks complement activity for one to two weeks after a single dose. Soliris was approved for the treatment of aHUS by the Food and Drug Administration (FDA) and the EC, during the year ended December 31, 2011. Soliris was granted orphan drug designation for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and Europe.